Last reviewed · How we verify
Cardiochirurgia E.H. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sucrosomial Iron | Sucrosomial Iron | marketed | Iron supplement | Hematology |
Therapeutic area mix
- Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- All India Institute of Medical Sciences · 1 shared drug class
- Clinica Fabia Mater · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Hatem AbuHashim · 1 shared drug class
- Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
- Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri · 1 shared drug class
- Laboratoire Innotech International · 1 shared drug class
- Abdelwahed, Mai Mahmoud Mohamed, M.D. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cardiochirurgia E.H.:
- Cardiochirurgia E.H. pipeline updates — RSS
- Cardiochirurgia E.H. pipeline updates — Atom
- Cardiochirurgia E.H. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cardiochirurgia E.H. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cardiochirurgia-e-h. Accessed 2026-05-16.